Blood stem cell transplantation for breast cancer: new approaches using pre- peri- post-transplant immunotherapy

Autologous peripheral blood stem cell transplantation (auto-PBSCT) after high dose chemotherapy is usually offered to breast cancer patients carrying a high risk of relapse or having chemosensitive metastatic disease. Whether progression free and overall survival of such patients is improved after auto-PBSCT compared to conventional chemotherapy is a matter of debate. Currently available results of randomised trials could not uniformly prove or disprove auto-PBSCT being advantageous. Yet such studies have not employed any manipulation of the stem cell graft or any post-transplant immunomodulation exploiting the unique immunological environment for tumour eradication which exists only after auto-PBSCT. Preliminary data have discussed the ex vivo and in vivo generation of cytotoxic effector cells employing IL-2 and/or IFN-α/γ in the auto-PBSCT setting. Other cytokines such as IL-12, IL-15 and prolactin have likewise been considered . Several anticancer vaccine protocols after auto-PBSCT are ongoing using monovalent vaccines or anti-idiotypic antibodies. Polyvalent anticancer vaccines, cytokine secreting tumour cells, tumour pulsed or hybridised dendritic cells (DC) enhanced with cytokines are studied. Monoclonal antibodies (mAb) could assist: unlabelled for pretransplant ex vivo purging, post-transplant for enhancing antibody-dependent cell mediated cytotoxicity (ADCC) or radioimmunoconjugated as an additive cytotoxic part of the conditioning regimen. Autologous graft versus host induction and allogeneic stem cell transplantation (probably with non-myeloablative conditioning followed by donor lymphocyte infusions) are other approaches. Evaluation of successful combinations, optimal dosages and appropriate timing schedules is the subject of future investigations. Since breast cancer patients belong to countless subgroups, a large number of protocols need to be addressed in order to avoid over treatment and prevent relapse.

[1]  R. Dillman,et al.  Interferon-Gamma or Granulocyte-Macrophage Colony-Stimulating Factor Administered as Adjuvants With a Vaccine of Irradiated Autologous Tumor Cells From Short-Term Cell Line Cultures: A Randomized Phase 2 Trial of the Cancer Biotherapy Research Group , 2003, Journal of immunotherapy.

[2]  S. Markovic,et al.  Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer , 2001, Bone Marrow Transplantation.

[3]  S. Swain,et al.  Interleukin 18 , 2001, The Journal of experimental medicine.

[4]  R. Storb,et al.  Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. , 2001, Blood.

[5]  M. Caligiuri,et al.  Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset , 2001 .

[6]  S. Markovic,et al.  Immune reconstitution after autologous hematopoietic stem cell transplantation. , 2001, Mayo Clinic proceedings.

[7]  J. Dancey,et al.  A randomized trial of high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell support (asct) compared to standard chemo therapy (ct) in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) clinical trials group study , 2001 .

[8]  E. Cohen.  DNA-based vaccines for the treatment of cancer--an experimental model. , 2001, Trends in molecular medicine.

[9]  E. Gehan,et al.  Ex vivo cytokine activation of peripheral blood stem cells: a potential role for adoptive cellular immunotherapy. , 2001, Journal of hematotherapy & stem cell research.

[10]  J. Blay,et al.  IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. , 2001, Cancer research.

[11]  R. Martuza,et al.  Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. , 2001, Cancer research.

[12]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[13]  H. Okamura,et al.  Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. , 2001, Cytokine & growth factor reviews.

[14]  N. Chao,et al.  Acute graft-vs-host disease: pathobiology and management. , 2001, Experimental hematology.

[15]  S. Slavin,et al.  Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[16]  Dr C. D. L. Reid.  Dendritic cells and immunotherapy for malignant disease , 2001, British journal of haematology.

[17]  J. Peschon,et al.  Ligation of 4-1BB (CDw137) Regulates Graft-Versus-Host Disease, Graft-Versus-Leukemia, and Graft Rejection in Allogeneic Bone Marrow Transplant Recipients1 , 2001, The Journal of Immunology.

[18]  K. Knutson,et al.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.

[19]  D. Huhn,et al.  Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. , 2001, Human gene therapy.

[20]  E. Jaffee,et al.  The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. , 2001, Cancer research.

[21]  T. Waldmann,et al.  Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. , 2001, Immunity.

[22]  K. Foon,et al.  The anti-idiotype vaccines for immunotherapy. , 2001, Current opinion in molecular therapeutics.

[23]  J. Sosman,et al.  Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Jäger,et al.  Challenges to the development of antigen-specific breast cancer vaccines , 2001, Breast Cancer Research.

[25]  S. Geyer,et al.  Lymphoid reconstitution Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer , 2001 .

[26]  C. White,et al.  Antibody-targeted immunotherapy for treatment of malignancy. , 2001, Annual review of medicine.

[27]  J. Kurebayashi.  Biological and clinical significance of her2 overexpression in Breast Cancer , 2001, Breast cancer.

[28]  T. Strom,et al.  IL-15 and IL-2: a matter of life and death for T cells in vivo , 2001, Nature Medicine.

[29]  G. Demetri,et al.  A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer , 2001, Bone Marrow Transplantation.

[30]  M. Bonamino,et al.  Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease , 2001, Bone Marrow Transplantation.

[31]  M. Caligiuri,et al.  Human natural killer cells : a unique innate immunoregulatory role for the CD 56 bright subset , 2001 .

[32]  G. Dranoff,et al.  Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. , 2001, Cancer research.

[33]  J. Talmadge,et al.  Mechanisms of immune dysfunction in stem cell transplantation. , 2000, International journal of immunopharmacology.

[34]  N. Schmitz,et al.  Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? , 2000 .

[35]  N. Brasseur,et al.  Eradication of Multiple Myeloma and Breast Cancer Cells by TH9402-mediated Photodynamic Therapy: Implication for Clinical Ex Vivo Purging of Autologous Stem Cell Transplants¶ , 2000, Photochemistry and photobiology.

[36]  J. Murray.  Monoclonal antibody treatment of solid tumors: a coming of age. , 2000, Seminars in oncology.

[37]  F. Baron,et al.  Clinical course and predictive factors for cyclosporin‐induced autologous graft‐versus‐host disease after autologous haematopoietic stem cell transplantation , 2000, British journal of haematology.

[38]  N. Schmitz,et al.  Is there a graft‐versus‐leukaemia effect in the absence of graft‐versus‐host disease in patients undergoing bone marrow transplantation for acute leukaemia? , 2000, British journal of haematology.

[39]  K. McIntyre,et al.  Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells , 2000, British Journal of Cancer.

[40]  Barrett Aj.  Conditioning regimens for allogeneic stem cell transplants. , 2000 .

[41]  B. Löwenberg,et al.  Developments in T-cell depletion of allogeneic stem cell grafts. , 2000, Current opinion in hematology.

[42]  S. Mann,et al.  Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. , 2000, Cancer research.

[43]  D. Reece,et al.  Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer , 2000, Bone Marrow Transplantation.

[44]  R. Elliott,et al.  Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients. , 2000, Cancer biotherapy & radiopharmaceuticals.

[45]  W. Linehan,et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.

[46]  P. Richardson,et al.  Status of high-dose chemotherapy for breast cancer: a review. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[47]  M. Mori,et al.  Prolactin in autoimmunity and antitumor defence , 2000, Journal of Neuroimmunology.

[48]  A. Vincent-Salomon,et al.  Recombinant Vaccinia Virus Encoding Human MUC1 and IL2 as Immunotherapy in Patients With Breast Cancer , 2000, Journal of immunotherapy.

[49]  D. Olive,et al.  Pilot study of immunotherapy with interleukin-2 after autologous stem cell transplantation in advanced breast cancers. , 2000, Anticancer research.

[50]  J. Shah,et al.  Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer , 2000, Cancer Gene Therapy.

[51]  J. Xiang,et al.  Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth , 2000, Cancer Gene Therapy.

[52]  G. Prud’homme,et al.  IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice , 2000, Gene Therapy.

[53]  T. Illidge,et al.  Radioimmunotherapy of cancer: using monoclonal antibodies to target radiotherapy. , 2000, Current pharmaceutical design.

[54]  M. Seifert,et al.  High-dose chemotherapy plus hematopoietic stem-cell rescue for metastatic breast cancer. , 2000, The New England journal of medicine.

[55]  E. Ogris,et al.  Elevation of plasma prolactin in patients undergoing autologous blood stem-cell transplantation for breast cancer: is its modulation a step toward posttransplant immunotherapy? , 2000, American journal of clinical oncology.

[56]  M. Morse.  Technology evaluation: Theratope, Biomira Inc. , 2000, Current opinion in molecular therapeutics.

[57]  A. Pecora,et al.  Treatment of leukemic relapse following unrelated umbilical cord blood transplantation with interleukin-2: potential for augmenting graft-versus-leukemia and graft-versus-host effects with cytokines , 2000, Bone Marrow Transplantation.

[58]  E. Winer,et al.  Phase II evaluation of thalidomide in patients with metastatic breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  A. Bernath,et al.  HER-2/neu protein-receptor-positive breast carcinoma: an immunologic perspective. , 2000, Annals of clinical and laboratory science.

[60]  R. Philip,et al.  Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model , 2000, Cancer Gene Therapy.

[61]  P. Richardson,et al.  Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer , 2000, Bone Marrow Transplantation.

[62]  A. Reiter,et al.  Current trends in the management of chronic myelogenous leukemia , 2000, Annals of Hematology.

[63]  P. Chiusolo,et al.  Autologous graft-versus-host disease after CD34+-purified autologous peripheral blood progenitor cell transplantation. , 2000, Journal of hematotherapy & stem cell research.

[64]  J. Radich,et al.  Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[65]  M. Reddish,et al.  Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine , 2000, Bone Marrow Transplantation.

[66]  A. Galy,et al.  Recovery of lymphocyte and dendritic cell subsets after autologous CD34+ cell transplantation , 2000, Bone Marrow Transplantation.

[67]  E. Sotomayor,et al.  Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. , 2000, Blood.

[68]  M. Boyer,et al.  New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells , 2000, Bone Marrow Transplantation.

[69]  S. Heimfeld,et al.  Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. , 2000, Blood.

[70]  K. Cornetta,et al.  The CC Chemokine CKβ-11/MIP-3β/ELC/Exodus 3 Mediates Tumor Rejection of Murine Breast Cancer Cells Through NK Cells1 , 2000, The Journal of Immunology.

[71]  B. Blom,et al.  Introduction: TH2-inducing DC2 for immunotherapy. , 2000, Blood.

[72]  S. Singhal,et al.  Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial , 2000, The Lancet.

[73]  C. Mullen,et al.  Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. , 2000, Blood.

[74]  D. Blaise,et al.  Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer , 2000, Bone Marrow Transplantation.

[75]  G. Hill,et al.  G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient. , 2000, Transplantation.

[76]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[77]  Terry L. Smith,et al.  Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. , 2000, Journal of the National Cancer Institute.

[78]  S. Forman,et al.  Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy. , 2000, The cancer journal from Scientific American.

[79]  G. Hortobagyi,et al.  Delphi‐panel analysis of appropriateness of high‐dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer , 2000, Clinical transplantation.

[80]  D. Jocham,et al.  Technology evaluation: TG-1031, Transgene SA. , 2000, Current opinion in molecular therapeutics.

[81]  J. Talmadge,et al.  Purging of human breast cancer cells from stem cell products with an adenovirus containing p53 , 2000, Cancer Gene Therapy.

[82]  R. Gress,et al.  Th2 and Tc2 Cells in the Regulation of GVHD, GVL, and Graft Rejection: Considerations for the Allogeneic Transplantation Therapy of Leukemia and Lymphoma , 2000, Leukemia & lymphoma.

[83]  K. Oshimi,et al.  A Metalloproteinase Inhibitor Prevents Acute Graft-Versus-Host Disease While Preserving the Graft-Versus-Leukaemia Effect of Allogeneic Bone Marrow Transplantation , 2000, Leukemia & lymphoma.

[84]  A. Hess,et al.  Autologous graft-versus-host disease , 1995, Journal of hematotherapy & stem cell research.

[85]  M. Colombo,et al.  Antitumor vaccination: where we stand. , 2000, Haematologica.

[86]  C. Thoburn,et al.  Complexity of effector mechanisms in cyclosporine-induced syngeneic graft-versus-host disease. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[87]  D. Weisdorf,et al.  Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. , 2000, Experimental hematology.

[88]  K. Cornetta,et al.  The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. , 2000, Journal of immunology.

[89]  R. Negrin,et al.  Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[90]  T. Whiteside,et al.  Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. , 2000, Journal of immunotherapy.

[91]  R. Storb,et al.  Mini-allografts: ongoing trials in humans , 2000, Bone Marrow Transplantation.

[92]  P. Wernet,et al.  Successful treatment of relapsed CML after cord blood transplantation with donor leukocyte infusion IL-2 and IFNα , 2000, Bone Marrow Transplantation.

[93]  R. García-Carbonero,et al.  High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma – a phase II study , 2000, Bone Marrow Transplantation.

[94]  Amela,et al.  CONVENTIONAL-DOSE CHEMOTHERAPY COMPARED WITH HIGH-DOSE CHEMOTHERAPY PLUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR METASTATIC BREAST CANCER , 2000 .

[95]  S. Brunet,et al.  Allogeneic peripheral blood stem cell transplantation with CD34+-cell selection and delayed T-cell add-back in adults. Results of a single center pilot study. , 2000, Haematologica.

[96]  T. Rasmussen,et al.  Selective loss of progenitor subsets following clinical CD34+ cell enrichment by magnetic field, magnetic beads or chromatography separation , 1999, Bone Marrow Transplantation.

[97]  G. Bellone,et al.  Up‐modulation of interferon‐γ mediates the enhancement of spontanous cytotoxicity in prolactin‐activated natural killer cells , 1999, Immunology.

[98]  J. Goldman,et al.  Donor lymphocyte infusions. , 1999, Current opinion in hematology.

[99]  J. Armitage,et al.  Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. , 1999, JAMA.

[100]  F F Becker,et al.  The removal of human breast cancer cells from hematopoietic CD34+ stem cells by dielectrophoretic field-flow-fractionation. , 1999, Journal of Hematotherapy & Stem Cell Research.

[101]  M. Levitt,et al.  The generation of human dendritic and NK cells from hemopoietic progenitors induced by interleukin‐15 , 1999, Journal of leukocyte biology.

[102]  G. Denardo,et al.  Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[103]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  K. Cornetta,et al.  Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action. , 1999, Human gene therapy.

[105]  R. Abrams,et al.  Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial , 1999, Bone Marrow Transplantation.

[106]  H. Buschiazzo,et al.  Graft versus host disease in autologous stem cell transplantation. , 1999, Journal of experimental & clinical cancer research : CR.

[107]  J. Taylor‐Papadimitriou,et al.  Treatment of breast cancer with fibroblasts transfected with DNA from breast cancer cells. , 1999, Journal of immunology.

[108]  J. Schlom,et al.  A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[109]  E. Thiel,et al.  Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[110]  J. Connors,et al.  Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  H. Roché,et al.  Intensification thérapeutique et autogreffe de cellules souches hématopoïétiques (CSH) dans le traitement des cancers du sein métastatiques : résultats du programme national Pegase 04 , 1999 .

[112]  A. Enk,et al.  Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. , 1999, Blood.

[113]  J. Dipersio,et al.  Immune reconstitution following allogeneic peripheral blood stem cell transplants , 1999, Bone Marrow Transplantation.

[114]  R. Henschler,et al.  Proliferation and survival of mammary carcinoma cells are influenced by culture conditions used for ex vivo expansion of CD34(+) blood progenitor cells. , 1999, Blood.

[115]  D. Taub,et al.  Use of Neuroendocrine Hormones to Promote Reconstitution after Bone Marrow Transplantation , 1999, Neuroimmunomodulation.

[116]  E. Gehan,et al.  Immunotherapy with interleukin-2 and α-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer , 1999, Bone Marrow Transplantation.

[117]  B. Asselain,et al.  [Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04]. , 1999, Hematology and Cell Therapy.

[118]  A. Grañena,et al.  Treatment with interleukin-2 (IL-2) and interferon (IFNalpha 2b) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse , 1999, Bone Marrow Transplantation.

[119]  K. Ino,et al.  Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products , 1999, Bone Marrow Transplantation.

[120]  J. Talmadge,et al.  IL‐2 Expansion of T and NK Cells from Growth Factor‐Mobilized Peripheral Blood Stem Cell Products: Monocyte Inhibition , 1998, Journal of immunotherapy.

[121]  A. Chang,et al.  Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[122]  D. Rubinstein,et al.  Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. , 1998, Blood.

[123]  M. Mielcarek,et al.  Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. , 1998, Blood.

[124]  Anita B. Roberts,et al.  REGULATION OF IMMUNE RESPONSES BY TGF-β* , 1998 .

[125]  J. McPherson,et al.  Prolactin is an antagonist of TGF-beta activity and promotes proliferation of murine B cell hybridomas. , 1998, Cellular immunology.

[126]  A. O’Garra,et al.  Cytokines induce the development of functionally heterogeneous T helper cell subsets. , 1998, Immunity.

[127]  G. Hortobagyi,et al.  Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  M. Mielcarek,et al.  Impaired Induction of the CD28-Responsive Complex in Granulocyte Colony-Stimulating Factor Mobilized CD4 T Cells , 1998 .

[129]  R. Bouabdallah,et al.  Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation. , 1997, European cytokine network.

[130]  F. Prósper,et al.  Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections. , 1997, Blood.

[131]  A. Mazumder,et al.  Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates , 1997, Bone Marrow Transplantation.

[132]  P. Kelly,et al.  Immune function of prolactin (PRL) and signal transduction by PRL/GH/cytokine receptors: specificity, redundancy and lessons from chimaeras. , 1997, Cytokines, cellular & molecular therapy.

[133]  S. Mackinnon.  11 Donor leukocyte infusions , 1997 .

[134]  A. Nagler,et al.  Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. , 1997, Blood.

[135]  C. Verfaillie,et al.  Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. , 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[136]  L. Villalón,et al.  Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study , 1997, Bone Marrow Transplantation.

[137]  S. Mackinnon.  Donor leukocyte infusions. , 1997, Bailliere's clinical haematology.

[138]  J. Vose,et al.  Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow , 1997, Bone Marrow Transplantation.

[139]  M. Mielcarek,et al.  Impaired Induction of the CD 28-Responsive Complex in Granulocyte Colony-Stimulating Factor Mobilized CD 4 T Cells , 1997 .

[140]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[141]  C. Marth,et al.  Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. , 1996, Blood.

[142]  L. Matera,et al.  Endocrine, paracrine and autocrine actions of prolactin on immune cells. , 1996, Life sciences.

[143]  A. Nagler,et al.  Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. , 1996, Blood.

[144]  J. Thompson,et al.  Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. , 1996, Blood.

[145]  T. Spitzer.  Allogeneic peripheral blood stem cell transplantation. , 1996, The Journal of infusional chemotherapy.

[146]  D. Carbone,et al.  Erratum: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells (Nature Medicine 2, 1096-1103 (1996)) , 1996 .

[147]  J. Ferrara,et al.  Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.

[148]  J. Ritz,et al.  Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. , 1994, Blood.

[149]  N. Davidson,et al.  Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  M. Rouleau,et al.  LONG‐TERM PERSISTENCE OF TRANSFERRED PPD‐REACTIVE T CELLS AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION , 1993, Transplantation.

[151]  E. Farmer,et al.  Acute Graft-vs-Host Disease: Development Following Autologous and Syngeneic Bone Marrow Transplantation , 1987 .

[152]  P. Hiestand,et al.  Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[153]  C. Huber,et al.  Effects of human recombinant alpha 2 arg-interferon and gamma-interferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression. , 1985, Cancer research.

[154]  R. Mertelsmann,et al.  Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2. , 1984, Blood.